Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TLC Stock Summary
In the News
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks Clinical benefits sustained to 24 weeks; second injection furthered benefits to 52 weeks
TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares
TAIPEI, Taiwan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company or TLC (Nasdaq: TLC, TWO: 4152, “the Company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced today that it has notified Nasdaq that it will apply for the voluntary delisting of its American depositary shares (“ADS”s) from the Nasdaq Global Market.
TLC Reports Second Quarter 2021 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.
Short Squeeze Stocks: XELA, NEGG and 3 Other Stocks Experts Think Are Ready to Pop
Looking for the next AMC, retail investors are on the hunt for the next squeeze. Here are five short squeeze stocks to watch this week.
TLC Announces Details of Stock Swap Transactions
TAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (Nasdaq: TLC, TWO: 4152, “the company”), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced details of the company's board-approved stock swap transactions with Woods Investment Company, Ltd. (“Woods”) at a press conference held at 4:00pm Taipei time at the Taipei Exchange (TPEx). Details of the stock swap transactions are as follows:
TLC Stock Price: 28.69% Increase Explanation
The stock price of TLC (Nasdaq: TLC) increased by 28.69% yesterday. This is why it happened.
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare Limited, part of Zydus Cadila group (Zydus) (NSE: CADILAHC), an innovative, global pharmaceutical group that discovers, develops, manufactures and markets a broad range of healthcare therapies, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India.
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?
Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) saw its shares surge in the last session with trading volume being higher than average.
TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment
India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's (NASDAQ: TLC) marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute liposomal amphotericin B shortage. AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis, a serious fungal infection known as a black fungus.
TLC Stock Price: Over 6% Increase Pre-Market Explanation
The stock price of Taiwan Liposome Company (NASDAQ: TLC) increased by over 6% pre-market. This is why it happened.
TLC Financial details
TLC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 1.51 | 1.79 | 1.99 | 6.38 | 2.58 | |
Net income per share | -29.78 | -31.5 | -28.75 | -24.64 | -24.89 | |
Operating cash flow per share | -21.96 | -29.52 | -21.88 | -23.73 | -22.15 | |
Free cash flow per share | -22.84 | -30.44 | -24.1 | -25.56 | -23.02 | |
Cash per share | 64.99 | 34.3 | 35.54 | 31.24 | 33.99 | |
Book value per share | 65.16 | 35.58 | 21.34 | 22.03 | 11.08 | |
Tangible book value per share | 65.16 | 35.58 | 21.21 | 21.97 | 21.83 | |
Share holders equity per share | 65.16 | 35.58 | 21.34 | 22.03 | 11.08 | |
Interest debt per share | 4.31 | 4.17 | 13.52 | 16.26 | 17.31 | |
Market cap | 5.18B | 4.78B | 5.27B | 5.27B | 4.92B | |
Enterprise value | 3.5B | 3.94B | 4.88B | 4.76B | 4.24B | |
P/E ratio | -6.28 | -5.47 | -5.85 | -6.53 | -5 | |
Price to sales ratio | 124.32 | 96.3 | 84.56 | 25.22 | 48.23 | |
POCF ratio | -8.52 | -5.83 | -7.68 | -6.78 | -5.62 | |
PFCF ratio | -8.19 | -5.66 | -6.97 | -6.3 | -5.4 | |
P/B Ratio | 2.87 | 4.84 | 7.88 | 7.31 | 11.23 | |
PTB ratio | 2.87 | 4.84 | 7.88 | 7.31 | 11.23 | |
EV to sales | 83.94 | 79.38 | 78.25 | 22.75 | 41.6 | |
Enterprise value over EBITDA | -4.69 | -4.82 | -5.78 | -6.72 | -4.66 | |
EV to operating cash flow | -5.76 | -4.81 | -7.11 | -6.12 | -4.85 | |
EV to free cash flow | -5.53 | -4.67 | -6.45 | -5.68 | -4.66 | |
Earnings yield | -0.16 | -0.18 | -0.17 | -0.15 | -0.2 | |
Free cash flow yield | -0.12 | -0.18 | -0.14 | -0.16 | -0.19 | |
Debt to equity | 0.06 | 0.11 | 0.62 | 0.71 | 1.52 | |
Debt to assets | 0.06 | 0.09 | 0.29 | 0.37 | 0.38 | |
Net debt to EBITDA | 2.26 | 1.03 | 0.47 | 0.73 | 0.74 | |
Current ratio | 9.85 | 5.45 | 3.45 | 1.97 | 4.11 | |
Interest coverage | -284.59 | -265.43 | -90.2 | -33.89 | -60.12 | |
Income quality | 0.74 | 0.94 | 0.76 | 0.96 | 0.89 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.4 | 2.72 | 2.37 | 0.8 | 1.43 | |
Research and developement to revenue | 17.68 | 16.38 | 13.36 | 4.11 | 9.49 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.04 | 0.03 | 0.1 | 0.08 | 0.04 | |
Capex to revenue | -0.59 | -0.51 | -1.12 | -0.29 | -0.34 | |
Capex to depreciation | -0.33 | -0.48 | -1.47 | -0.84 | -0.61 | |
Stock based compensation to revenue | 2.41 | 1.15 | 0.66 | 0.13 | 0.17 | |
Graham number | 208.95 | 158.81 | 117.49 | 110.51 | 78.79 | |
ROIC | -0.44 | -0.82 | -0.82 | -0.61 | -0.84 | |
Return on tangible assets | -0.39 | -0.69 | -0.64 | -0.58 | -0.56 | |
Graham Net | 54.91 | 25.16 | 12.09 | 11.45 | 12.23 | |
Working capital | 1.67B | 858.82M | 844.41M | 538.92M | 1.08B | |
Tangible asset value | 1.8B | 987.28M | 665.17M | 720.11M | 862.33M | |
Net current asset value | 1.57B | 776.62M | 439.97M | 431.55M | 545.84M | |
Invested capital | 0.06 | 0.11 | 0.62 | 0.71 | 1.52 | |
Average receivables | 26.29M | 25.4M | 23.16M | 19.15M | 28.05M | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 193.05 | 211.51 | 102.78 | 36.22 | 126.58 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 1.89 | 1.73 | 3.55 | 10.08 | 2.88 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.46 | -0.89 | -1.35 | -1.12 | -2.25 | |
Capex per share | -0.89 | -0.91 | -2.23 | -1.83 | -0.87 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
Metric | History | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.32 | 1.57 | 0.29 | 0.89 | 3.81 | |
Net income per share | -6.56 | -5.56 | -6.96 | -4.78 | -1.79 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | -0.47 | 0 | 0 | 0 | |
Cash per share | 33.41 | 0 | 31.94 | 25.64 | 0 | |
Book value per share | 25.76 | 17.19 | 10.42 | 5.6 | 3.59 | |
Tangible book value per share | 25.76 | 17.19 | 20.52 | 15.21 | 13.21 | |
Share holders equity per share | 25.76 | 17.19 | 10.42 | 5.6 | 3.59 | |
Interest debt per share | 0 | 0 | 15.88 | 0 | 0 | |
Market cap | 6.59B | 5.4B | 5.23B | 7.24B | 6.99B | |
Enterprise value | 5.36B | 5.4B | 4.55B | 6.16B | 6.99B | |
P/E ratio | -6.8 | -5.78 | -4.47 | -8.99 | -23.13 | |
Price to sales ratio | 559.71 | 81.68 | 432.83 | 192.46 | 43.62 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | -271.96 | 0 | 0 | 0 | |
P/B Ratio | 6.92 | 7.47 | 11.94 | 30.7 | 46.29 | |
PTB ratio | 6.92 | 7.47 | 11.94 | 30.7 | 46.29 | |
EV to sales | 454.85 | 81.68 | 376.95 | 163.75 | 43.62 | |
Enterprise value over EBITDA | -22.13 | -24.42 | -15.58 | -30.63 | -92.98 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | -271.96 | 0 | 0 | 0 | |
Earnings yield | -0.04 | -0.04 | -0.06 | -0.03 | -0.01 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 1.52 | 0 | 0 | |
Debt to assets | 0 | 0 | 0.38 | 0 | 0 | |
Net debt to EBITDA | 5.1 | 0 | 2.31 | 5.37 | 0 | |
Current ratio | 5.83 | 4.06 | 4.11 | 3.1 | 3.01 | |
Interest coverage | 0 | 0 | 0 | 0 | 0 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.35 | 0.58 | 2.92 | 0.83 | 0.2 | |
Research and developement to revenue | 19.44 | 4.11 | 22.78 | 5.92 | 1.37 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | -0.3 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -1.59 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 61.66 | 46.37 | 40.4 | 24.54 | 12.03 | |
ROIC | -0.27 | -0.34 | -0.23 | -0.92 | -0.61 | |
Return on tangible assets | -0.14 | -0.16 | -0.17 | -0.13 | -0.06 | |
Graham Net | 12.42 | -18.17 | 11.49 | 5.01 | -18.42 | |
Working capital | 1.16B | 873.11M | 1.08B | 795.14M | 659.03M | |
Tangible asset value | 951.99M | 722.44M | 862.33M | 640.63M | 555.78M | |
Net current asset value | 630.08M | 394.89M | 545.84M | 304.85M | 211.68M | |
Invested capital | 0 | 0 | 1.52 | 0 | 0 | |
Average receivables | 0 | 0 | 17.67M | 17.67M | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 263.28 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0.34 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.25 | -0.32 | -0.67 | -0.85 | -0.5 | |
Capex per share | 0 | -0.47 | 0 | 0 | 0 |
TLC Frequently Asked Questions
What is Taiwan Liposome Company, Ltd. stock symbol ?
Taiwan Liposome Company, Ltd. is a TW stock and trading under the symbol TLC
What is Taiwan Liposome Company, Ltd. stock quote today ?
Taiwan Liposome Company, Ltd. stock price is $7 today.
Is Taiwan Liposome Company, Ltd. stock public?
Yes, Taiwan Liposome Company, Ltd. is a publicly traded company.